ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
|Videos|February 17, 2017
Pharmacy Week in Review: February 17, 2017
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advertisement
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advertisement
Related to this article
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Long-Term Care Pharmacies Can Close the Flu Vaccination Gap Among Older Adults
4
Narrow Therapeutic Index Chemotherapy Dosing With eGFR: Safeguards for Oncology Pharmacists
5